App-Quantinova.ai

Association of co-occurring gene alterations and clinical activity of rucaparib in patients with BRCA1 or BRCA2 mutated (BRCA+) metastatic castration-resistant prostate cancer (mCRPC).

Wassim Abida - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Rucaparib

Multimodal biomarkers overcome sampling bias to predict presence of aggressive localized prostate cancer.

David Monty Berman - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

N/A

1L pembrolizumab (pembro) versus chemotherapy (chemo) for choice-of-carboplatin patients with advanced urothelial carcinoma (UC) in KEYNOTE-361.

Thomas Powles - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced Urothelial Carcinoma

Pembrolizumab

Efficacy of platinum re-challenge in metastatic urothelial carcinoma (mUC): A retrospective comparison of chemotherapy regimens.

Risa Liang Wong - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced Urothelial Carcinoma

N/A

Impact of subsequent therapy on survival in KEYNOTE-361: Pembrolizumab (pembro) plus chemotherapy (chemo) or pembro alone versus chemo as first-line therapy for advanced urothelial carcinoma (UC).

Ajjai Shivaram Alva - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced Urothelial Carcinoma

Pembrolizumab

P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumors (GCTs).

Shalini Subramaniam - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Germ cell tumor

PEGylated G-CSF

Patterns of progression in patients treated with nivolumab plus ipilimumab (NIVO+IPI) versus sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214.

Nizar M. Tannir - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic Renal Cell Cancer

Ipilimumab

Outcomes for patients in the pembrolizumab+axitinib arm with advanced renal cell carcinoma (RCC) who completed two years of treatment in the phase III KEYNOTE-426 study.

Elizabeth R. Plimack - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic Renal Cell Cancer

Pembrolizumab

Nivolumab + cabozantinib (NIVO+CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): Outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER.

Robert J. Motzer - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic Renal Cell Cancer

Cabozantinib

CTC counts as a biomarker of prognosis and response in metastatic castration-resistant prostate cancer (mCRPC) from the CARD trial.

Johann S. De Bono - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

N/A

SAPROCAN: Saracatinib (AZD0530) and docetaxel in metastatic,castrate-refractory prostate cancer (mCRPC)—A phase I/randomized phase II study by the United Kingdom National Cancer Research Institute Prostate Group.

Robert J. Jones - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

saracatinib

Genomic analysis of circulating tumor DNA in 3,334 patients with advanced prostate cancer to identify targetable BRCA alterations and AR resistance mechanisms.

Hanna Tukachinsky - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

N/A

A phase I study of capivasertib in combination with abiraterone acetate in patients with metastatic castration-resistant prostate cancer.

Neal D. Shore - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Racial diversity and reporting in FDA registration trials for genitourinary (GU) cancers from 2006-20.

Mark Lythgoe - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

A phase III trial of capivasertib and abiraterone versus placebo and abiraterone in patients with de novo metastatic hormone-sensitive prostate cancer characterized by PTEN deficiency (CAPItello-281).

Karim Fizazi - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

CB-7598

Open-label, phase II study of ladiratuzumab vedotin (LV) for castration-resistant prostate cancer (SGNLVA-005, trial-in-progress).

Amna Falak Sher - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

SGN-LIV1A

The BARCODE1 pilot study targeting men with increased genetic risk of developing prostate cancer: Examining the feasibility of a community-based screening program using polygenic risk score to target screening.

Jana Kathlyn McHugh - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

N/A

Localized activation of the metastatic phenotype within the perineural region in prostate cancer.

Mick D. Brown - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

N/A

A single-blinded, multicenter, randomized controlled trial to evaluate NeuroSAFE robotic-assisted radical prostatectomy (RARP) versus standard robotic-assisted radical prostatectomy (RARP) in men with localized prostate cancer: NeuroSAFE PROOF—Trial in progress.

Eoin Dinneen - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

N/A

Association between sites of metastases (mets) and outcomes with immune checkpoint inhibitor (ICI) therapy for advanced urothelial carcinoma (aUC).

Dimitrios Makrakis - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Advanced Urothelial Carcinoma

N/A

Filters

45280 Abstracts